Have a feature idea you'd love to see implemented?
Let us know!
NRIX Nurix Therapeutics Inc
Price (delayed)
$18.6
Market cap
$1.32B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.91
Enterprise value
$1.24B
Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer
Highlights
NRIX's equity has surged by 61% year-on-year
NRIX's debt is down by 6% since the previous quarter
NRIX's quick ratio is up by 22% year-on-year but it is down by 5% since the previous quarter
The net income has declined by 19% year-on-year and by 7% since the previous quarter
NRIX's gross profit is down by 18% YoY and by 9% from the previous quarter
Key stats
What are the main financial stats of NRIX
Market
Valuations
Earnings
Shares outstanding
70.84M
Market cap
$1.32B
Enterprise value
$1.24B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.18
Price to sales (P/S)
23.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
22.06
Revenue
$56.42M
Gross profit
$56.42M
Net income
-$176.98M
EBIT
-$176.71M
EBITDA
-$160.83M
Free cash flow
-$106.9M
Per share
Balance sheet
Liquidity
EPS
-$2.91
EPS diluted
-$2.91
Free cash flow per share
-$1.47
Book value per share
$5.85
Revenue per share
$0.78
TBVPS
$7.06
Total assets
$513.6M
Total liabilities
$136.74M
Debt
$27.14M
Equity
$376.86M
Working capital
$369.75M
Debt to equity
0.07
Current ratio
5.28
Quick ratio
5.2
Net debt/EBITDA
0.45
Margins
Efficiency
Dividend
EBITDA margin
-285%
Gross margin
100%
Net margin
-313.7%
Operating margin
-343.3%
Return on assets
-41.8%
Return on equity
-63.4%
Return on invested capital
-61.8%
Return on capital employed
-41.4%
Return on sales
-313.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NRIX stock price
How has the Nurix Therapeutics stock price performed over time
Intraday
-2.16%
1 week
-1.59%
1 month
-8.24%
1 year
98.51%
YTD
-1.27%
QTD
-1.27%
Financial performance
How have Nurix Therapeutics's revenue and profit performed over time
Revenue
$56.42M
Gross profit
$56.42M
Operating income
-$193.7M
Net income
-$176.98M
Gross margin
100%
Net margin
-313.7%
Nurix Therapeutics's operating margin has decreased by 49% YoY and by 19% QoQ
NRIX's net margin is down by 45% year-on-year and by 18% since the previous quarter
The operating income has declined by 22% year-on-year and by 8% since the previous quarter
The net income has declined by 19% year-on-year and by 7% since the previous quarter
Growth
What is Nurix Therapeutics's growth rate over time
Valuation
What is Nurix Therapeutics stock price valuation
P/E
N/A
P/B
3.18
P/S
23.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
22.06
NRIX's EPS is down by 6% year-on-year
NRIX's equity has surged by 61% year-on-year
The stock's price to book (P/B) is 10% more than its 5-year quarterly average of 2.9 and 10% more than its last 4 quarters average of 2.9
The stock's price to sales (P/S) is 57% more than its last 4 quarters average of 15.3 but 7% less than its 5-year quarterly average of 25.8
The revenue has contracted by 18% YoY and by 9% from the previous quarter
Efficiency
How efficient is Nurix Therapeutics business performance
NRIX's return on sales is down by 45% year-on-year and by 18% since the previous quarter
The ROE has contracted by 14% YoY but it has grown by 6% from the previous quarter
NRIX's return on invested capital is up by 6% since the previous quarter but it is down by 5% year-on-year
NRIX's return on assets is up by 6% since the previous quarter
Dividends
What is NRIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NRIX.
Financial health
How did Nurix Therapeutics financials performed over time
Nurix Therapeutics's total liabilities has surged by 84% YoY but it has decreased by 2.6% QoQ
The total assets has surged by 67% year-on-year
NRIX's debt is 93% smaller than its equity
The debt to equity has surged by 133% year-on-year but it has declined by 13% since the previous quarter
NRIX's equity has surged by 61% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.